BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 225521)

  • 1. Herpes simplex virus type 1 infection of isogenic Epstein-Barr virus genome-negative and -positive Burkitt's lymphoma-derived cell lines.
    Leinbach SS; Summers WC
    J Virol; 1979 Apr; 30(1):248-54. PubMed ID: 225521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary EBV infection of human umbilical cord lymphocytes and EBV genome-negative lymphoblastoid cell lines (BJAB and Ramos).
    Takimoto T; Sato H; Ogura H
    Auris Nasus Larynx; 1986; 13(3):199-205. PubMed ID: 3036055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between Epstein-Barr virus (EBV) and human cell lines: growth and EBV induction.
    Takimoto T; Iwawaki J; Tanaka S; Umeda R
    ORL J Otorhinolaryngol Relat Spec; 1990; 52(1):40-6. PubMed ID: 2154734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between growth characteristics of an Epstein--Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.
    Steinitz M; Klein G
    Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3518-20. PubMed ID: 171663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible DNA-RNA tumor virus interaction in human lymphomas: expression of retroviral proteins in Ramos lymphoma lines is enhanced after conversion with Epstein-Barr virus.
    Lasky RD; Troy FA
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):33-7. PubMed ID: 6320170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
    Fresen KO; zur Hausen H
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two ebv-negative lymphoma lines and their EBV-converted sublines.
    Ernberg I; Klein G; Giovanella BC; Stehlin J; McCormick KJ; Andersson-Anvret M; Aman P; Killander D
    Int J Cancer; 1983 Feb; 31(2):163-9. PubMed ID: 6298125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.
    Fresen KO; Merkt B; Bornkamm GW; Hausen H
    Int J Cancer; 1977 Mar; 19(3):317-23. PubMed ID: 191406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-induced increase in the concanavalin-A receptor density of established EBV-negative lymphoma lines in vitro.
    Siegert W; Mönch T; Valet G
    Exp Hematol; 1980 Nov; 8(10):1173-82. PubMed ID: 6262102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
    Fresen KO; Hausen H
    Int J Cancer; 1976 Feb; 17(2):161-6. PubMed ID: 175026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene expression in isogenic, EBV-positive and -negative Burkitt lymphoma cell lines.
    Glazer PM; Summers WC
    Intervirology; 1985; 23(2):82-9. PubMed ID: 2984143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines.
    Dillner J; Kallin B; Alexander H; Ernberg I; Uno M; Ono Y; Klein G; Lerner RA
    Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6641-5. PubMed ID: 3018741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA.
    Clements GB; Klein G; Povey S
    Int J Cancer; 1975 Jul; 16(1):125-33. PubMed ID: 170210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular size variation of EBNA is determined by the EB viral genome.
    Gergely L; Sternås L; Dillner J; Klein G
    Intervirology; 1984; 22(2):85-96. PubMed ID: 6090339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
    Béchet JM; Guétard D
    Int J Cancer; 1983 Jul; 32(1):61-5. PubMed ID: 6305854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus.
    Rooney C; Howe JG; Speck SH; Miller G
    J Virol; 1989 Apr; 63(4):1531-9. PubMed ID: 2538644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent herpes simplex virus infections established in two Burkitt lymphoma derived cell lines.
    Robey WG; Graham BJ; Harris CL; Madden MJ; Pearson GR; Vande Woude GF
    J Gen Virol; 1976 Jul; 32(1):51-62. PubMed ID: 182914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the protein composition of Epstein-Barr Virus-negative lymphoma cells after EBV-conversion.
    Siegert W; Mönch T
    Anticancer Res; 1983; 3(1):11-6. PubMed ID: 6299173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
    J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transcriptional mechanisms of deregulation of MYC following conversion of a human B cell line by Epstein-Barr virus.
    Lacy J; Summers WP; Summers WC
    EMBO J; 1989 Jul; 8(7):1973-80. PubMed ID: 2551670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.